Inventiva SA
PAR:IVA
Inventiva SA
Total Equity
Inventiva SA
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inventiva SA
PAR:IVA
|
Total Equity
-€106.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Equity
€181.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Innate Pharma SA
PAR:IPH
|
Total Equity
€8.8m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-19%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Equity
€97.4m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Equity
$79.2m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
10%
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Total Equity
€178.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
41%
|
CAGR 10-Years
24%
|
|
Inventiva SA
Glance View
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
See Also
What is Inventiva SA's Total Equity?
Total Equity
-106.6m
EUR
Based on the financial report for Dec 31, 2024, Inventiva SA's Total Equity amounts to -106.6m EUR.
What is Inventiva SA's Total Equity growth rate?
Total Equity CAGR 1Y
-233%
Over the last year, the Total Equity growth was -233%.
You don't have any saved screeners yet